The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network
This open-label study (n=9) investigated the effects of ayahuasca (123,2mg DMT, 32,34mg Harmine) on the functional brain connectivity of experienced users, and found a decrease in the activity of core structures of the Default Mode Network (DMN).
Authors
- Fernanda Palhano-Fontes
- Jamie Hallak
- Luiz Tófoli
Published
Abstract
Introduction
The experiences induced by psychedelics share a wide variety of subjective features, related to the complex changes in perception and cognition induced by this class of drugs. A remarkable increase in introspection is at the core of these altered states of consciousness. Self-oriented mental activity has been consistently linked to the Default Mode Network (DMN), a set of brain regions more active during rest than during the execution of a goal-directed task.
Methods
Here we used fMRI technique to inspect the DMN during the psychedelic state induced by Ayahuasca in ten experienced subjects. Ayahuasca is a potion traditionally used by Amazonian Amerindians composed by a mixture of compounds that increase monoaminergic transmission. In particular, we examined whether Ayahuasca changes the activity and connectivity of the DMN and the connection between the DMN and the task-positive network (TPN).
Results
Ayahuasca caused a significant decrease in activity through most parts of the DMN, including its most consistent hubs: the Posterior Cingulate Cortex (PCC)/Precuneus and the medial Prefrontal Cortex (mPFC). Functional connectivity within the PCC/Precuneus decreased after Ayahuasca intake. No significant change was observed in the DMN-TPN orthogonality.
Discussion
Altogether, our results support the notion that the altered state of consciousness induced by Ayahuasca, like those induced by psilocybin (another serotonergic psychedelic), meditation and sleep, is linked to the modulation of the activity and the connectivity of the DMN.
Research Summary of 'The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network'
Introduction
Palhano-Fontes and colleagues frame their study within growing evidence that serotonergic psychedelics produce profound alterations in perception, cognition and self-related processing. The authors note that increased introspection is a hallmark of these states and that introspective, internally oriented mental activity has been consistently linked to the Default Mode Network (DMN), a set of brain regions more active at rest than during externally directed tasks. Previous work has shown DMN modulation in a variety of altered states (sleep, meditation, sedation) and after psilocybin; the authors therefore sought to test whether ayahuasca, a brew containing DMT plus monoamine oxidase inhibitors, similarly alters DMN activity and connectivity. This study set out to examine three related questions: whether acute ayahuasca intake changes DMN activity during an active task (verbal fluency), whether resting-state functional connectivity among DMN nodes is altered, and whether the relationship (orthogonality/anti-correlation) between the DMN and the task-positive network (TPN) is affected. The authors hypothesised that, given ayahuasca’s introspective effects and parallels with psilocybin and meditation, DMN activity would be reduced and DMN connectivity altered during the psychedelic state.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topic
- Authors
- APA Citation
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015). The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLOS ONE, 10(2), e0118143. https://doi.org/10.1371/journal.pone.0118143
References (10)
Papers cited by this study that are also in Blossom
Callaway, J. C., Mckenna, D. J., Grob, C. S. et al. · Journal of Ethnopharmacology (1999)
McKenna, D., Towers, G. H., Abbott, F. · Journal of Ethnopharmacology (1984)
De Araujo, D. B., Ribeiro, S., Cecchi, G. A. et al. · Human Brain Mapping (2011)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M. et al. · Psychopharmacology (2013)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Ray, T. S. · PLOS ONE (2010)
Hayashi, T., Vaupel, D. B., Su, T. P. · Science Signaling (2009)
Cited By (140)
Papers in Blossom that reference this study
Girn, M., Doss, M. K., Roseman, L. et al. · Nature Medicine (2026)
Silva-Costa, N., Pessoa, J. A., Andrade, K. C. et al. · Journal of Psychopharmacology (2025)
Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)
Rego Ramos, L., Fernandes Jr, O., Arruda Sanchez, T. · Journal of Magnetic Resonance Imaging (2025)
Suay, D., Aicher, H. D., Singer, B. et al. · Journal of Psychopharmacology (2025)
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I. et al. · Neuropsychopharmacology (2025)
Stoliker, D., Novelli, L., Khajehnejad, M. et al. · Biorxiv (2025)
Shinozuka, K., Jerotic, K., Mediano, P. A. M. et al. · Translational Psychiatry (2024)
Caspani, G., Ruffell, S. G. D., Tsang, WF. et al. · Pharmacological Research (2024)
Nicol, G. E. · Nature (2024)
Show all 140 papersShow fewer
Bagdasarian, F. A., Hansen, H. D., Chen, J. et al. · ACS Chemical Neuroscience (2024)
Shinozuka, K., Tewarie, P. K. B., Luppi, A. et al. · Biorxiv (2024)
Pasquini, L., Simon, A. J., Gallen, C. L. et al. · Biorxiv (2024)
Erritzoe, D., Timmermann, C., Godfrey, K. et al. · Nature Mental Health (2024)
Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · NeuroImage (2024)
Ramaekers, J. G., Mallaroni, P., Kloft, L. et al. · Journal of Cognitive Neuroscience (2023)
Vohryzek, J., Cabral, J., Timmermann, C. et al. · National Science Review (2023)
Lawrence, D. W., Timmermann, C. · Journal of Psychoactive Drugs (2023)
Adamska, I., Finc, K. · Psychopharmacology (2023)
Girn, M., Rosas, F. E., Daws, R. E. et al. · Trends in Cognitive Sciences (2023)
Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2023)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Ponomarenko, P., Seragnoli, F., Calder, A. et al. · Journal of Psychopharmacology (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Perkins, D., Ruffell, S. G. D., day, K. et al. · Frontiers in Neuroscience (2023)
Modlin, N. L., Miller, T. M., Rucker, J. J. et al. · Journal of Affective Disorders (2023)
Ledwos, N., Rodas, J. D., Husain, M. I. et al. · Journal of Psychopharmacology (2022)
Wall, M., Nutt, D. J., Kaelen, M. et al. · Journal of Psychopharmacology (2022)
Bouso, J. C., Andión, O., Sarris, J. et al. · PLOS Global Public Health (2022)
Gukasyan, N., Schreyer, C. C., Griffiths, R. R. et al. · Current Psychiatry Reports (2022)
Guss, J. · Psychoanalytic Dialogues (2022)
Perkins, D., Pagni, B. A., Sarris, J. et al. · Frontiers in Pharmacology (2022)
Gattuso, J. J., Perkins, D., Ruffell, S. G. D. et al. · International Journal of Neuropsychopharmacology (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Costa, M. A. · Journal of Psychoactive Drugs (2022)
Pontual, A. A. D. D., Tófoli, L. F., Corradi-Webster, C. M. et al. · Frontiers in Psychology (2022)
Luppi, A. I., Hansen, J. Y., Adapa, R. et al. · Biorxiv (2022)
Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)
Kohek, M., Ona, G., Dos Santos, R. G. et al. · Journal of Psychoactive Drugs (2022)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Orłowski, P., Ruban, A., Szczypiński, J. et al. · Journal of Psychopharmacology (2022)
Gill, H., Puramat, P., Patel, P. et al. · Psychiatry Research (2022)
Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)
Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)
Reckweg, J., Uthaug, M. V., Szabo, A. et al. · Journal of Neurochemistry (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Stoliker, D., Novelli, L., Vollenweider, F. X. et al. · MedRvix (2021)
Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)
Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)
Ona, G., Berrada, A., Bouso, J. C. · Transcultural Psychiatry (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Ona, G., Sampedro, F., Romero, S. et al. · International Journal of Neuropsychopharmacology (2021)
Castelhano, J. M., Lima, G. M., Teixeira, M. et al. · Frontiers in Pharmacology (2021)
Domenico, C., Haggerty, D., Mou, X. et al. · Cell Reports (2021)
Dos Santos, R. G., Osório, F. L., Rocha, J. M. et al. · Journal of Clinical Psychopharmacology (2021)
Ruffell, S. G. D., Netzband, N., Tsang, W. et al. · Frontiers in Psychiatry (2021)
Bement, W., Banks, M. I., Zahid, Z. et al. · Molecular Biology of the Cell (2021)
Rush, B., Marcus, O., García, S. et al. · Frontiers in Pharmacology (2021)
Uthaug, M. V., Davis, A. K., Davis, D. et al. · Journal of Psychopharmacology (2021)
Rodrigues, L. S., Rossi, G. N., Rocha, J. M. et al. · European Archives of Psychiatry and Clinical Neuroscience (2021)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)
Jobst, B. M., Atasoy, S., Ponce-Alvarez, A. et al. · NeuroImage (2021)
Dos Santos, R. G., Hallak, J. E., Baker, G. et al. · Journal of Psychopharmacology (2021)
Pasquini, L., Luke, D., Harris, R. E. et al. · Frontiers in Human Neuroscience (2021)
Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
Pallavicini, C., Cavanna, F., Zamberlan, F. et al. · Journal of Psychopharmacology (2021)
Bouso, J. C., Ona, G., Dos Santos, R. G. et al. · Advances in Experimental Medicine and Biology (2021)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Hibicke, M., Gobbi, G. · Journal of Neuroscience (2020)
Kadriu, B., Greenwald, M., Ba et al. · International Journal of Neuropsychopharmacology (2020)
Holze, F., Dolder, P. C., Ley, L. et al. · Neuropsychopharmacology (2020)
Alamia, A., Timmermann, C., Carhart-Harris, R. L. · eLife (2020)
Doss, M. K., May, D. G., Johnson, M. W. et al. · Scientific Reports (2020)
Johnson, S., Black, Q. C. · International Journal of Mental Health and Addiction (2020)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Netzband, N., Ruffell, S., Linton, &. S. et al. · Psychopharmacology (2020)
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N. et al. · Journal of Psychopharmacology (2020)
Jacobs, E. · Journal of Psychedelic Studies (2020)
Girn, M., Mills, C., Roseman, L. et al. · NeuroImage (2020)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Girn, M., Roseman, L., Bernhardt, B. et al. · Biorxiv (2020)
Pasquini, L., Palhano-Fontes, F., Araújo, D. B. · Journal of Psychopharmacology (2020)
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G. et al. · Scientific Reports (2020)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Murphy-Beiner, A., Soar, K. · Psychopharmacology (2020)
Ho, J. T., Preller, K. H., Lenggenhager, B. · Neuroscience and Biobehavioral Reviews (2020)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Pallavicini, C., Vilas, M. G., Villarreal, M. et al. · NeuroImage (2019)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychology of Consciousness Theory Research and Practice (2019)
Carhart-Harris, R. L. · Current Opinion in Psychiatry (2019)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Lyons, T., Carhart-Harris, R. L. · Frontiers in Psychology (2018)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Uthaug, M. V., Van Oorsouw, &. K., Kuypers, &. K. P. C. et al. · Psychopharmacology (2018)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Kuypers, K. P. C. · Medical Hypotheses (2018)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Dos Santos, R. G., Osório, F. L., Hallak, J. E. · Archives of Clinical Psychiatry (São Paulo) (2018)
Barsuglia, J. P., Polanco, M., Palmer, R. et al. · Progress in Brain Research (2018)
Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)
Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)
Riga, M. S., Llad O-Pelfort, L., Artigas, F. et al. · Neuropharmacology (2017)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Winkelman, M. J. · Frontiers in Neuroscience (2017)
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)
Bøhling, F. · International Journal of Drug Policy (2017)
Viol, A., Palhano-Fontes, F., Onias, H. et al. · Scientific Reports (2017)
Elsey, J. W. B. · Drug Science Policy and Law (2017)
Letheby, C., Gerrans, P. · Neuroscience of Consciousness (2017)
Kaelen, M., Lorenz, R., Barrett, F. S. et al. · Biorxiv (2017)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Talin, P., Sanabria, E. · International Journal of Drug Policy (2017)
Millière, R. · Frontiers in Human Neuroscience (2017)
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Kaelen, M. · Imperial College London (2017)
Dos Santos, R. G., Hallak, J. E., Bouso, J. C. · Therapeutic Advances in Psychopharmacology (2017)
Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Bouso, J. C., Pedrero-Pérez, E. J., Gandy, S. · Human Psychopharmacology (2016)
Tófoli, L. F., De Araujo, D. B. · International Review of Neurobiology (2016)
Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Dos Santos, R. G., Balthazar, F. M., Bouso, J. C. et al. · Journal of Psychopharmacology (2016)
Nunes, A. A., Dos Santos, R. G., Osório, F. L. et al. · Journal of Psychoactive Drugs (2016)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Nichols, D. E. · Pharmacological Reviews (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Therapeutic Advances in Psychopharmacology (2016)
Speth, J., Speth, C., Kaelen, M. et al. · Journal of Psychopharmacology (2016)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Alonso, J. N., Romero, S., Mañanas, M. A. et al. · International Journal of Neuropsychopharmacology (2015)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.